With Up to 8 Years of Therapy, Asciminib (ASC) Monotherapy Demonstrated Continued Favorable Efficacy, Safety, and Tolerability in Patients (pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (ph+ CML-CP) Without the T315I Mutation: Final Results from the Phase 1 X2101 Study